Amgen's Broad Portfolio Strength and Wide Moat Should Protect Profits Despite Upcoming Biosimilars
Biosimilars have been on the market in Europe since 2007 but have had a larger impact on Amgen since 2019 as US exposure intensifies. Pressure on Prolia/Xgeva is coming in 2025. Amgen's pipeline had ...
Zacks.com on MSN19h
AMGN's Q4 Earnings Beat, Obesity Candidate Under FDA Clinical Hold
Amgen AMGN reported fourth-quarter 2024 adjusted earnings of $5.31 per share, which beat the Zacks Consensus Estimate of ...
BioSpace22h
Pipeline Problems Mar Amgen’s Q4 Beat
Amgen outperformed expectations in the fourth quarter of 2024, but revealed an FDA hold on early-stage obesity asset AMG 513 ...
4AMGN : Amgen Options Trading: A Deep Dive into Market Sentiment
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks ...